Chembio, AIDS Healthcare Foundation to test 1 million people for HIV
NEW YORK Chembio Diagnostics and the AIDS Healthcare Foundation are marking World AIDS Day 2008 in a global effort to test 1 million people for HIV, Chembio announced Monday.
For the campaign, which started Wednesday and ends Monday, Chembio has provided about 20,000 of its HIV 1/2 Stat-Pak tests to testing programs in three countries.
According to UNAIDS, there were 33.2 million people living with HIV worldwide last year, a 14 percent increase from 2001.
“We are proud to support AIDS Healthcare Foundation and the World AIDS Day 2008 One Million Tests Campaign by providing access to rapid HIV testing,” Chembio president and chief executive officer Lawrence Siebert said in astatement. “Being tested and knowing one’s HIV status is the critical first step in obtaining treatment and preventing further transmission of disease.”
NOCA recognizes PTCB’s Corrigan with Certification Industry Leadership Award
WASHINGTON Melissa Murer Corrigan, executive director and chief executive officer of the Pharmacy Technician Certification Board, has received the 2008 Certification Industry Leadership Award from the National Organization for Competency Assurance, PTCB announced Tuesday.
PTCB said the award recognized Murer Corrigan’s leadership in the field of certification and licensure. She has certified more than 320,000 pharmacy technicians as the founding executive of PTCB.
“This award is a tribute to the hard work and dedication of all my colleagues and partners involved in making PTCB a success since our founding in 1995,” Murer Corrigan said in a statement. “The certification of pharmacy technicians in the U.S. has advanced the patient safety of millions of Americans, and I am so proud of the PTCB team and all of our certified technicians.”
FDA warns Shionogi to end unsupported Cedax claims
ROCKVILLE, Md. The Food and Drug Administration released a warning letter to Shionogi and Co. Tuesday regarding its antibiotic Cedax.
The FDA said the company made inflated claims about Cedax (ceftibuten) and downplayed the health risks associated with it. Promotional materials sent to doctors claimed the drug had “excellent tolerability,” even though data did not support the claim.
The drug is approved for treating mild to moderate bacterial infections.